Teva Launches Methotrexate Injection
Teva announced the launch of Methotrexate Injection in NovaPlus label. Methotrexate, an antimetabolite, is a folic acid antagonist used to treat certain types of cancer including cancers that begin in the tissues that form around a fertilized egg in the uterus, breast cancer, lung cancer, certain cancers of the head and neck, certain types of lymphoma, and leukemia. It is also used to treat severe psoriasis and active rheumatoid arthritis (RA).
Methotrexate inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair, and cellular replication. Teva received approval for Methotrexate Injection in June 2012.
Methotrexate Injection is available as a 25mg/mL concentration in 2mL and 10mL glass vials.For more information call (888) 482-9522 or visit www.tevausa.com